The CONTIGO Foundation subsidizes a study against breast cancer for Dr. Diego Marzese

The researcher Diego Marzesefrom the Cancer Epigenetics Laboratory of the IdISBa Cancer Cell Biology group, will lead the study financed by the Fundación CONTIGO Contra el Cancer de la Mujer to identify new strategies that improve the efficiency of immunotherapy in triple negative breast cancer.

The CONTIGO Foundation will finance the research project with a financial contribution of €100,999.80.

The research will be carried out mainly in the IdISBa Cancer Epigenetics Laboratory and will have the collaboration of doctors and researchers from the Son Espases University Hospital, the University of the Balearic Islands, Duke University, the University of California, Los Angeles (UCLA ), Saint John’s Hospital Cancer Institute (SJCI), and the University of Southern California (USC).

This study aims to improve the treatment of Triple Negative Breast Cancer through therapeutic modulation of epigenetic mechanisms and splicing alternatively involved in immune evasion. Triple-negative breast cancer accounts for around 15% of breast tumors and is more aggressive and has a worse prognosis, since it does not have specific treatments.

In recent years, immunotherapy has become an alternative for the treatment of many tumor types. This therapeutic strategy is based on boosting the patient’s own immune system to locate and destroy cancer cells. However, some cancer cells find strategies to resist this type of treatment, basically through their ability to camouflage themselves and stop being seen by the cells of the immune system.

This adaptation requires, among other factors, a different maturation of the genes through mechanisms of splicing alternative. If we see DNA as an instruction book where each gene is a chapter, the splicing alternative would allow the editor to skip certain paragraphs or include others that should not be in the final version, thus changing the meaning of the message. These pathological changes are regulated or trigger epigenetic mechanisms, which are not only dynamic, but also reversible.

Therefore, the study will evaluate new therapeutic targets that make it possible to reverse immune evasion mechanisms. In this way, the cancer cells would lose their ability to camouflage themselves and would again be visible to the cells of the immune system, allowing immunotherapy to once again be an effective treatment in patients with triple negative breast cancer.

The CONTIGO Foundation, led by Dr. Javier Cortés, supports research projects that can contribute to early diagnosis and offer a personalized therapeutic strategy against female cancer.

[Fuente: IdISBa. 06/05/2022]

[Foto: IdISBa]